Hema Mehta

Hema Mehta has a diverse work experience spanning multiple roles and companies. They started their career as a Healthcare Advisor at Alliance Boots from August 2011 to May 2018. Following this, they worked at the University of Oxford, initially as a Research Assistant from October 2014 to August 2017. They then pursued a DPhil in Clinical Medicine from September 2017 to November 2020, during which they conducted research on the role of MAIT cells in the liver environment, liver disease, and hepatocellular carcinoma. They used various techniques such as purification methods, functional assays, flow cytometry, and sequencing. Additionally, they investigated tumor microenvironment-derived prostaglandin modulation of MAIT function and conducted deep phenotyping of conventional and innate-like T cells in liver disease using high dimensional spectral flow cytometry.

From January 2021, Hema Mehta joined the University of Oxford again, this time as a Postdoctoral Researcher. In this position, their primary focus has been on characterizing the immune response in severe acute COVID-19 patients who have received convalescent plasma therapy. They utilized high dimensional spectral flow cytometry to investigate all major immune cell subsets in this unique cohort.

More recently, Hema Mehta became associated with Scancell Ltd in July 2022 as a Scientist. Further details about their role at Scancell Ltd are not provided in the data.

Hema Mehta completed their education with a BSc (Hons) in Biomedical Science from St George's, University of London (for students and alumni) in 2011. In 2012, they pursued a Masters in Immunology from King's College London. From 2017 to 2020, they attended the University of Oxford to earn their Doctor of Philosophy - PhD in Clinical and Experimental Medicine.